ConductScience.org, home

Paper19084016

Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.

Liu CJ and 18 others. Gastroenterology, 2009. Cited by 170 papers, by iCite.

Cite this record

ConductScience Library. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Papers, record 19084016. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19084016

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.
PubMed
Journal
Gastroenterology
PubMed
Year
2009
PubMed
Publication types
Comparative Study, Controlled Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
170
iCite
Relative citation ratio, by iCite
4.66
iCite
Revised in PubMed
2026-01-28
PubMed

Authors19

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Liu CJChun-Jen
2Chuang WLWan-Long
3Lee CMChuan-Mo
4Yu MLMing-Lung
5Lu SNSheng-Nan
6Wu SSShun-Sheng
7Liao LYLi-Ying
8Chen CLChi-Ling
9Kuo HTHsing-Tao
10Chao YCYou-Chen
11Tung SYShui-Yi
12Yang SSSien-Sing
13Kao JHJia-Horng
14Liu CHChen-Hua
15Su WWWei-Wen
16Lin CLChih-Lin
17Jeng YMYung-Ming
18Chen PJPei-Jer
19Chen DSDing-Shinn

Source PubMed

Download CSV of authors

Topics23

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antiviral AgentsMajor topic
Hepatitis BMajor topic
Hepatitis CMajor topic
Interferon-alphaMajor topic
Polyethylene GlycolsMajor topic
RibavirinMajor topic
Adult
Antibodies, Viral
DNA, Viral
Dose-Response Relationship, Drug
Drug Therapy, Combination
Female
Hepacivirus
Hepatitis B virus
Humans
Interferon alpha-2
Male
Middle Aged
Recombinant Proteins
Taiwan
Treatment Outcome
Viral Interference
Viral Load

Source PubMed

Download CSV of topics

Trials2

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT00361179Long Term Effects of Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C/B Co-Infection and Chronic Hepatitis CDerived from the trialYesClinicalTrials.gov
NCT02060058Boceprevir-based Therapy to Rescue HCV Genotype 1/HBV Infected Patients Refractory to Combination TherapyBackgroundClinicalTrials.gov

Download CSV of trials

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in19105960Treatment of HBV/HCV coinfection: releasing the enemy within.https://conductscience.org/library/papers/19105960

Source PubMed

Download CSV of comments and corrections

Cited by70

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 170 citations.

PMIDTitleJournalYearIn PapersSource
41508339Treatment strategies for patients with hepatitis B virus infection coexisting with hepatitis C virus or metabolic dysfunction-associated steatotic liver disease.Clin Mol Hepatol2026https://conductscience.org/library/papers/41508339PubMed
40445953Risk of HBV reactivation in HBV/HCV-co-infected HCV-treated patients: A single-center study.PLoS One2025https://conductscience.org/library/papers/40445953PubMed
39971544[Research progress on hepatitis B combined with C and its treatment].Zhonghua Gan Zang Bing Za Zhi2024https://conductscience.org/library/papers/39971544PubMed
39743539HBV DNA integration and somatic mutations in HCC patients with HBV-HCV dual infection reveals profiles intermediate between HBV- and HCV-related HCC.J Biomed Sci2025https://conductscience.org/library/papers/39743539PubMed
36004906A Biotechnological Approach for the Production of Pharmaceutically Active Human Interferon-α from Raphanus sativus L. Plants.Bioengineering (Basel)2022https://conductscience.org/library/papers/36004906PubMed
34864948Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up at 108 Weeks Posttreatment.Clin Infect Dis2022https://conductscience.org/library/papers/34864948PubMed
34365587Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH).Hepatol Int2021https://conductscience.org/library/papers/34365587PubMed
33765123The endoplasmic reticulum unfolded protein response - homeostasis, cell death and evolution in virus infections.FEMS Microbiol Rev2021https://conductscience.org/library/papers/33765123PubMed
32875000Viral Interference Between Dengue Virus and Hepatitis C Virus Infections.Open Forum Infect Dis2020https://conductscience.org/library/papers/32875000PubMed
32664198Hepatitis C Virus and Hepatitis B Virus Co-Infection.Viruses2020https://conductscience.org/library/papers/32664198PubMed
31565002Impact of chronic schistosomiasis and HBV/HCV co-infection on the liver: current perspectives.Hepat Med2019https://conductscience.org/library/papers/31565002PubMed
31540223Hepatitis B Virus (HBV) Reactivation Following Pharmacological Eradication of Hepatitis C Virus (HCV).Viruses2019https://conductscience.org/library/papers/31540223PubMed
31357767[Research progress of hepatitis B and C virus co-infection].Zhonghua Gan Zang Bing Za Zhi2019https://conductscience.org/library/papers/31357767PubMed
31276038Economic evaluation of direct-acting antivirals for the treatment of genotype 3 hepatitis C infection in Singapore.JGH Open2019https://conductscience.org/library/papers/31276038PubMed
30992821Viral hepatitis B coinfection with human immunodeficiency virus, hepatitis D virus, or hepatitis C virus.Clin Liver Dis (Hoboken)2013https://conductscience.org/library/papers/30992821PubMed
30557991A scoring system to predict HBsAg seroclearance in hepatitis B and C coinfected patients treated with interferon and ribavirin in an Asian cohort.Medicine (Baltimore)2018https://conductscience.org/library/papers/30557991PubMed
30543053Engineering Chlamydomonas reinhardtii for Expression of Functionally Active Human Interferon-α.Mol Biotechnol2019https://conductscience.org/library/papers/30543053PubMed
30271742HBV-HCV Coinfection: Viral Interactions, Management, and Viral Reactivation.J Clin Transl Hepatol2018https://conductscience.org/library/papers/30271742PubMed
300926242017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C.Clin Mol Hepatol2018https://conductscience.org/library/papers/30092624PubMed
30065564Hepatitis B reactivation in patients receiving direct-acting antiviral therapy or interferon-based therapy for hepatitis C: A systematic review and meta-analysis.World J Gastroenterol2018https://conductscience.org/library/papers/30065564PubMed

See all 70 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
IFNA23440PubTator's text mininghttps://conductscience.org/library/genes/3440

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/19084016

GET https://conductscience.org/api/papers/v1/19084016/cited_by?page=2